BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$1.17 USD
0.00 (0.00%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $1.17 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBioXcel Therapeutics, Inc. (BTAI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.40 | $10.00 | $4.00 | 447.01% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for BioXcel Therapeutics, Inc. comes to $6.40. The forecasts range from a low of $4.00 to a high of $10.00. The average price target represents an increase of 447.01% from the last closing price of $1.17.
Analyst Price Targets (5 )
Broker Rating
BioXcel Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, three are Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/15/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Hold | Hold |
6/27/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
3/18/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
2/21/2024 | UBS | Colin N Bristow | Not Available | Hold |
1/3/2024 | Guggenheim Securities | Yatin Suneja | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 6 |
Average Target Price | $6.40 |
LT Growth Rate | 37.10% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | -0.76 |